Senetek acquires rights to additional anti-cancer RNAi technology
Senetek, a US life sciences company that develops technologies targeting the science of healthy aging, has signed an agreement with the Institute of Bioorganic Chemistry of the Polish Academy of Sciences in Poland for the exclusive rights to a new tumour treatment using an RNAi-based therapeutic technology for use against a broad range of cancers.
Senetek, a US life sciences company that develops technologies targeting the science of healthy aging, has signed an agreement with the Institute of Bioorganic Chemistry of the Polish Academy of Sciences in Poland for the exclusive rights to a new tumour treatment using an RNAi-based therapeutic technology for use against a broad range of cancers.
This technology, which targets a cancer biomarker, was developed by the Institute with the Department of Neurosurgery and Neurotraumatology at the University of Medical Sciences in Poznań. Under the terms of the agreement, Senetek will have rights for all applications of the in-licensed technologies in exchange for undisclosed royalty payments to be paid on commercialisation.